MWNA
VYGR icon

Marshall Wace North America’s Voyager Therapeutics VYGR Stock Holding History

Marshall Wace North America’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,023
Closed -$28K – 1511
2020
Q1 		$28K Buy
+3,023
New +$34.7K ﹤0.01% 1121
2019
Q1 		– Sell
-3,400
Closed -$32K – 1930
2018
Q4 		$32K Buy
+3,400
New +$43.6K ﹤0.01% 1349

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Marshall Wace North America's VYGR Position: Q2 2020 in Review

Marshall Wace North America sold out of Voyager Therapeutics (VYGR) in Q2 2020, closing a stake of 3,023 shares — an estimated $28K sold.

Marshall Wace North America first reported a position in VYGR in Q4 2018 and held it in 2 quarters. The position peaked at $32K in Q4 2018. 113 funds tracked by Wall St. Rank hold VYGR as of Q2 2020.

  • Marshall Wace North America reported no remaining Voyager Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Marshall Wace North America sold 3,023 Voyager Therapeutics shares in Q2 2020, an estimated $28K.
  • Marshall Wace North America first reported a position in Voyager Therapeutics in Q4 2018 and held it in 2 quarters.
  • Marshall Wace North America's Voyager Therapeutics position peaked at $32K in Q4 2018.
  • 113 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2020.

Based on Marshall Wace North America's 13F filing for Q2 2020, filed 13 Aug 2020.